BACKGROUND: Castration-resistant prostate cancer (PCa) represents a serious health challenge. Based on mechanistically-supported rationale we explored new therapeutic options based on clinically available drugs with anticancer effects, including inhibitors of PARP1 enzyme (PARPi), and histone deacetylases (vorinostat), respectively, and disulfiram (DSF, known as alcohol-abuse drug Antabuse) and its copper-chelating metabolite CuET that inhibit protein turnover. METHODS: Drugs and their combination with ionizing radiation (IR) were tested in various cytotoxicity assays in three human PCa cell lines including radio-resistant stem-cell like derived cells. Mechanistically, DNA damage repair, heat shock and unfolded protein response (UPR) pathways were assessed by immunofluorescence and immunoblotting. RESULTS: We observed enhanced sensitivity to PARPi/IR in PC3 cells consistent with lower homologous recombination (HR) repair. Vorinostat sensitized DU145 cells to PARPi/IR and decreased mutant p53. Vorinostat also impaired HR-mediated DNA repair, as determined by Rad51 foci formation and downregulation of TOPBP1 protein, and overcame radio-resistance of stem-cell like DU145-derived cells. All PCa models responded well to CuET or DSF combined with copper. We demonstrated that DSF interacts with copper in the culture media and forms adequate levels of CuET indicating that DSF/copper and CuET may be considered as comparable treatments. Both DSF/copper and CuET evoked hallmarks of UPR in PCa cells, documented by upregulation of ATF4, CHOP and phospho-eIF2α, with ensuing heat shock response encompassing activation of HSF1 and HSP70. Further enhancing the cytotoxicity of CuET, combination with an inhibitor of the anti-apoptotic protein survivin (YM155, currently undergoing clinical trials) promoted the UPR-induced toxicity, yielding synergistic effects of CuET and YM155. CONCLUSIONS: We propose that targeting genotoxic and proteotoxic stress responses by combinations of available drugs could inspire innovative strategies to treat castration-resistant PCa.

Danish Cancer Society Research Center Copenhagen Denmark Division of Genome Biology Department of Medical Biochemistry and Biophysics Science for Life Laboratory Karolinska Institute Stockholm Sweden

Department of Clinical and Molecular Pathology Institute of Molecular and Translational Medicine Faculty of Medicine and Dentistry Palacky University Olomouc Czech Republic

Department of Genome Integrity Institute of Molecular Genetics of the CAS v v i Prague Czech Republic

Department of Oncology Faculty of Medicine and Dentistry Palacky University University Hospital Olomouc Czech Republic

Laboratory of Genome Integrity Institute of Molecular and Translational Medicine Faculty of Medicine and Dentistry Palacky University Olomouc Czech Republic

Laboratory of Genome Integrity Institute of Molecular and Translational Medicine Faculty of Medicine and Dentistry Palacky University Olomouc Czech Republic Danish Cancer Society Research Center Copenhagen Denmark Division of Genome Biology Department of Medical Biochemistry and Biophysics Science for Life Laboratory Karolinska Institute Stockholm Sweden Department of Genome Integrity Institute of Molecular Genetics of the CAS v v i Prague Czech Republic

000      

00000naa a2200000 a 4500

001      

bmc19045108

003      

CZ-PrNML

005      

20220216131638.0

007      

ta

008      

200109s2019 xxu f 000 0|eng||

009      

AR

024    7_

$a 10.1002/pros.23741 $2 doi

035    __

$a (PubMed)30499118

040    __

$a ABA008 $b cze $d ABA008 $e AACR2

041    0_

$a eng

044    __

$a xxu

100    1_

$a Majera, Dusana $u Laboratory of Genome Integrity, Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic.

245    10

$a Targeting genotoxic and proteotoxic stress-response pathways in human prostate cancer by clinically available PARP inhibitors, vorinostat and disulfiram / $c D. Majera, Z. Skrott, J. Bouchal, J. Bartkova, D. Simkova, M. Gachechiladze, J. Steigerova, D. Kurfurstova, J. Gursky, G. Korinkova, K. Cwiertka, Z. Hodny, M. Mistrik, J. Bartek,

520    9_

$a BACKGROUND: Castration-resistant prostate cancer (PCa) represents a serious health challenge. Based on mechanistically-supported rationale we explored new therapeutic options based on clinically available drugs with anticancer effects, including inhibitors of PARP1 enzyme (PARPi), and histone deacetylases (vorinostat), respectively, and disulfiram (DSF, known as alcohol-abuse drug Antabuse) and its copper-chelating metabolite CuET that inhibit protein turnover. METHODS: Drugs and their combination with ionizing radiation (IR) were tested in various cytotoxicity assays in three human PCa cell lines including radio-resistant stem-cell like derived cells. Mechanistically, DNA damage repair, heat shock and unfolded protein response (UPR) pathways were assessed by immunofluorescence and immunoblotting. RESULTS: We observed enhanced sensitivity to PARPi/IR in PC3 cells consistent with lower homologous recombination (HR) repair. Vorinostat sensitized DU145 cells to PARPi/IR and decreased mutant p53. Vorinostat also impaired HR-mediated DNA repair, as determined by Rad51 foci formation and downregulation of TOPBP1 protein, and overcame radio-resistance of stem-cell like DU145-derived cells. All PCa models responded well to CuET or DSF combined with copper. We demonstrated that DSF interacts with copper in the culture media and forms adequate levels of CuET indicating that DSF/copper and CuET may be considered as comparable treatments. Both DSF/copper and CuET evoked hallmarks of UPR in PCa cells, documented by upregulation of ATF4, CHOP and phospho-eIF2α, with ensuing heat shock response encompassing activation of HSF1 and HSP70. Further enhancing the cytotoxicity of CuET, combination with an inhibitor of the anti-apoptotic protein survivin (YM155, currently undergoing clinical trials) promoted the UPR-induced toxicity, yielding synergistic effects of CuET and YM155. CONCLUSIONS: We propose that targeting genotoxic and proteotoxic stress responses by combinations of available drugs could inspire innovative strategies to treat castration-resistant PCa.

650    _2

$a nádorové buněčné linie $7 D045744

650    _2

$a oprava DNA $x účinky léků $7 D004260

650    _2

$a disulfiram $x terapeutické užití $7 D004221

650    _2

$a regulace genové exprese u nádorů $x účinky léků $7 D015972

650    _2

$a lidé $7 D006801

650    _2

$a mužské pohlaví $7 D008297

650    _2

$a cílená molekulární terapie $x metody $7 D058990

650    _2

$a buňky PC-3 $7 D000078722

650    _2

$a fosfohydroláza PTEN $x genetika $7 D051059

650    _2

$a PARP inhibitory $x terapeutické užití $7 D000067856

650    _2

$a nádory prostaty $x farmakoterapie $7 D011471

650    _2

$a tolerance záření $7 D011836

650    _2

$a rekombinační oprava DNA $x účinky léků $7 D059767

650    _2

$a fyziologický stres $x účinky léků $x genetika $7 D013312

650    _2

$a nádorový supresorový protein p53 $x genetika $7 D016159

650    _2

$a vorinostat $x terapeutické užití $7 D000077337

655    _2

$a časopisecké články $7 D016428

655    _2

$a práce podpořená grantem $7 D013485

700    1_

$a Skrott, Zdenek $u Laboratory of Genome Integrity, Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic.

700    1_

$a Bouchal, Jan $u Department of Clinical and Molecular Pathology, Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic.

700    1_

$a Bartkova, Jirina $u Danish Cancer Society Research Center, Copenhagen, Denmark. Division of Genome Biology, Department of Medical Biochemistry and Biophysics, Science for Life Laboratory, Karolinska Institute, Stockholm, Sweden.

700    1_

$a Simkova, Dana $u Department of Clinical and Molecular Pathology, Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic.

700    1_

$a Gachechiladze, Mariam $u Department of Clinical and Molecular Pathology, Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic.

700    1_

$a Steigerova, Jana $u Department of Clinical and Molecular Pathology, Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic.

700    1_

$a Kurfürstová, Daniela $u Department of Clinical and Molecular Pathology, Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic. $7 xx0269558

700    1_

$a Gursky, Jan $u Laboratory of Genome Integrity, Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic.

700    1_

$a Korinkova, Gabriela $u Department of Clinical and Molecular Pathology, Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic.

700    1_

$a Cwiertka, Karel $u Department of Oncology, Faculty of Medicine and Dentistry, Palacky University, University Hospital, Olomouc, Czech Republic.

700    1_

$a Hodny, Zdenek $u Department of Genome Integrity, Institute of Molecular Genetics of the CAS, v.v.i., Prague, Czech Republic.

700    1_

$a Mistrik, Martin $u Laboratory of Genome Integrity, Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic.

700    1_

$a Bartek, Jiri $u Laboratory of Genome Integrity, Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic. Danish Cancer Society Research Center, Copenhagen, Denmark. Division of Genome Biology, Department of Medical Biochemistry and Biophysics, Science for Life Laboratory, Karolinska Institute, Stockholm, Sweden. Department of Genome Integrity, Institute of Molecular Genetics of the CAS, v.v.i., Prague, Czech Republic.

773    0_

$w MED00010484 $t The Prostate $x 1097-0045 $g Roč. 79, č. 4 (2019), s. 352-362

856    41

$u https://pubmed.ncbi.nlm.nih.gov/30499118 $y Pubmed

910    __

$a ABA008 $b sig $c sign $y a $z 0

990    __

$a 20200109 $b ABA008

991    __

$a 20220216131633 $b ABA008

999    __

$a ok $b bmc $g 1483377 $s 1083781

BAS    __

$a 3

BAS    __

$a PreBMC

BMC    __

$a 2019 $b 79 $c 4 $d 352-362 $e 20181129 $i 1097-0045 $m The Prostate $n Prostate $x MED00010484

GRA    __

$a NV15-28628A $a NV16-32030A $p MZ0 $p MZ0

GRA    __

$a NV15-28628A $a NV16-32030A $p MZ0 $p MZ0

LZP    __

$a Pubmed-20200109